{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:46:26Z","timestamp":1773974786107,"version":"3.50.1"},"posted":{"date-parts":[[2025,11,24]]},"group-title":"In Review","reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,3]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Early data suggest metabolic dysfunction-associated steatotic liver disease (MASLD) associates with increased fractures. However, absolute risk, subpopulations at greatest risk, and risk basis are unknown. We use a two-pronged approach to address these gaps: we investigated fracture risk among humans with MASLD and mechanisms among diet-induced animal model of NAFLD (DIAMOND\u2122) mice. We interrogated the TriNetX US collaborative database, propensity-matching people with MASLD 10-fold with people with metabolic dysfunction alone. All-fracture and pathological-fracture risks are elevated among people\u2009&gt;\u200951 years of age with MASLD. DIAMOND mice with MASLD lost bone thickness, strength, and bone formation and gained increased bone resorption. MASLD associated with differential expression of key indicators of bone loss: decreased hepatic\n                  <italic>igf1<\/italic>\n                  and\n                  <italic>cyp2r1<\/italic>\n                  , increased hepatic\n                  <italic>fgf21, ctgf<\/italic>\n                  , and\n                  <italic>anxa2<\/italic>\n                  , decreased skeletal\n                  <italic>bglap, runx2<\/italic>\n                  , and\n                  <italic>postn<\/italic>\n                  , and increased skeletal\n                  <italic>pparg<\/italic>\n                  . These expression changes are supported by increased serum FGF21, reported in literature to impair bone anabolism. Herein, we establish MASLD as a risk factor for fracture and propose putative mechanisms driving bone loss.\n                <\/p>","DOI":"10.21203\/rs.3.rs-7775325\/v1","type":"posted-content","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:51:51Z","timestamp":1763992311000},"source":"Crossref","is-referenced-by-count":1,"title":["MASLD and MASH increase fracture risk in humans and mice by arresting new bone formation"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-3161","authenticated-orcid":false,"given":"Galen","family":"Goldscheitter","sequence":"first","affiliation":[{"name":"Virginia Commonwealth University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Jahagirdar","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulugeta","family":"Seneshaw","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faridoddin","family":"Mirshahi","sequence":"additional","affiliation":[{"name":"Div. of Gastroenterology, Hepatology and Nutrition, Dept. of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Summerlin","sequence":"additional","affiliation":[{"name":"Georgia Institute of Technology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Ip","sequence":"additional","affiliation":[{"name":"University of Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Coelho","sequence":"additional","affiliation":[{"name":"Yale University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Buettmann","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian","family":"Genetos","sequence":"additional","affiliation":[{"name":"University of California Davis College of Veterinary Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-5748","authenticated-orcid":false,"given":"Arun","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Donahue","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University College of Engineering"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi ZM","unstructured":"Younossi, Z.M., Kalligeros, M., Henry, L.: Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol. 31, S32\u2013S50 (Aug. 2024). 10.3350\/cmh.2024.0431 Suppl","journal-title":"Clin. Mol. Hepatol."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1503519","author":"Diehl AM","year":"2017","unstructured":"Diehl, A.M., Day, C.: Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis, New England Journal of Medicine, vol. 377, no. 21, pp. 2063\u20132072, Nov. (2017). 10.1056\/NEJMra1503519"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"155642","DOI":"10.1016\/J.METABOL.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi P","unstructured":"Golabi, P., et al.: Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States. Metabolism. 146, 155642 (Sep. 2023). 10.1016\/J.METABOL.2023.155642","journal-title":"Metabolism"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5009\/gnl210571","article-title":"Relationship between the High Fatty Liver Index and Risk of Fracture","volume":"17","author":"Kim M-J","unstructured":"Kim, M.-J., Kim, M.-S., Lee, H.-B., Roh, J.-H., Jeon, J.-H.: Relationship between the High Fatty Liver Index and Risk of Fracture. Gut Liver. 17(1), 119\u2013129 (Jan. 2023). 10.5009\/gnl210571","journal-title":"Gut Liver"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00408","author":"Wang Y","year":"2018","unstructured":"Wang, Y., et al.: Association of Nonalcoholic Fatty Liver Disease With Osteoporotic Fractures: A Cross-Sectional Retrospective Study of Chinese Individuals, Front Endocrinol (Lausanne), vol. 9, [Online]. Available: https:\/\/www.frontiersin.org\/articles\/ (2018). 10.3389\/fendo.2018.00408"},{"issue":"3","key":"ref6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/joim.13497","article-title":"Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: A nationwide population-based cohort study","volume":"292","author":"Wester A","unstructured":"Wester, A., Hagstr\u00f6m, H.: Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: A nationwide population-based cohort study. J. Intern. Med. 292(3), 492\u2013500 (Sep. 2022). https:\/\/doi.org\/10.1111\/joim.13497","journal-title":"J. Intern. Med."},{"issue":"6","key":"ref7","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1210\/jc.2011-3010","article-title":"Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese","volume":"97","author":"Li M","unstructured":"Li, M., et al.: Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J. Clin. Endocrinol. Metab. 97(6), 2033\u20132038 (Jun. 2012). 10.1210\/jc.2011-3010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"ref8","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00198-022-06459-y","article-title":"Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"33","author":"Pan B","year":"2022","unstructured":"Pan, B., et al.: Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Osteoporos. Int. 33(11), 2275\u20132286 (2022). 10.1007\/s00198-022-06459-y","journal-title":"Osteoporos. Int."},{"issue":"1","key":"ref9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bmb\/ldaa005","article-title":"The epidemiology of osteoporosis","volume":"133","author":"Clynes MA","unstructured":"Clynes, M.A., Harvey, N.C., Curtis, E.M., Fuggle, N.R., Dennison, E.M., Cooper, C.: The epidemiology of osteoporosis. Br. Med. Bull. 133(1), 105\u2013117 (May 2020). 10.1093\/bmb\/ldaa005","journal-title":"Br. Med. Bull."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1586\/17446651.2015.1077697","author":"Mabilleau G","year":"2015","unstructured":"Mabilleau, G., Chappard, D., Flatt, P.R., Irwin, N.: Effects of anti-diabetic drugs on bone metabolism, Expert Rev Endocrinol Metab, vol. 10, no. 6, pp. 663\u2013675, Nov. (2015). 10.1586\/17446651.2015.1077697"},{"issue":"10","key":"ref11","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1001\/archinte.1991.00400100100017","article-title":"A Model of Lifetime Osteoporosis Impact","volume":"151","author":"Chrischilles EA","unstructured":"Chrischilles, E.A., Butler, C.D., Davis, C.S., Wallace, R.B.: A Model of Lifetime Osteoporosis Impact. Arch. Intern. Med. 151(10), 2026\u20132032 (Oct. 1991). 10.1001\/archinte.1991.00400100100017","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","article-title":"A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer","volume":"65","author":"Asgharpour A","unstructured":"Asgharpour, A., et al.: A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J. Hepatol. 65(3), 579\u2013588 (Sep. 2016). 10.1016\/j.jhep.2016.05.005","journal-title":"J. Hepatol."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01043-6","author":"Vacca M","year":"2024","unstructured":"Vacca, M., et al.: Jun., An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD), Nature Metabolism 2024 6:6, vol. 6, no. 6, pp. 1178\u20131196, (2024). 10.1038\/s42255-024-01043-6"},{"issue":"1","key":"ref14","doi-asserted-by":"publisher","first-page":"23090","DOI":"10.1038\/s41598-025-08693-w","article-title":"Sexual dimorphism of MASLD-driven bone loss","volume":"15","author":"Goldscheitter GM","year":"2025","unstructured":"Goldscheitter, G.M., et al.: Sexual dimorphism of MASLD-driven bone loss. Sci. Rep. 15(1), 23090 (2025). 10.1038\/s41598-025-08693-w","journal-title":"Sci. Rep."},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead P","year":"2017","unstructured":"Bankhead, P., et al.: QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7(1), 16878 (2017). 10.1038\/s41598-017-17204-5","journal-title":"Sci. Rep."},{"key":"ref16","author":"Brunt EM","year":"2011","unstructured":"Brunt, E.M., Kleiner, D.E., Wilson, L.A., Belt, P.: B. A. Neuschwander-Tetri, and for the N. C. R. N. (CRN), Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings\u00a7\u2206, Hepatology, vol. 53, no. 3, [Online]. (2011). Available: https:\/\/journals.lww.com\/hep\/fulltext\/2011\/03000\/nonalcoholic_fatty_liver_disease__nafld__activity.12.aspx"},{"key":"ref17","author":"Mantovani A","year":"2019","unstructured":"Mantovani, A., et al.: Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis, Hepatology, vol. 70, no. 3, [Online]. (2019). Available: https:\/\/journals.lww.com\/hep\/fulltext\/2019\/09000\/association_between_nonalcoholic_fatty_liver.5.aspx"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4862","article-title":"Nonalcoholic Fatty Liver Disease Is Associated With Decreased Bone Mineral Density in Adults: A Systematic Review and Meta-Analysis","author":"Su Y-H","year":"2023","unstructured":"Su, Y.-H., Chien, K.-L., Yang, S.-H., Chia, W.-T., Chen, J.-H., Chen, Y.-C.: Nonalcoholic Fatty Liver Disease Is Associated With Decreased Bone Mineral Density in Adults: A Systematic Review and Meta-Analysis. J. Bone Min. Res. (2023). 10.1002\/jbmr.4862","journal-title":"J. Bone Min. Res."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00003086-199102000-00004","article-title":"Bone Growth Factors","volume":"263","author":"Mohan S","year":"1991","unstructured":"Mohan, S., Baylink, D.J.: Bone Growth Factors. Clin. Orthop. Relat. Res. no. 263, 30\u201348 (1991)","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/clinchem\/45.8.1384","article-title":"Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications","volume":"45","author":"Rosen CJ","year":"1999","unstructured":"Rosen, C.J.: Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. Clin. Chem. no. 45(8), 1384\u20131390 (1999)","journal-title":"Clin. Chem."},{"issue":"4","key":"ref21","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1359\/jbmr.2002.17.4.570","article-title":"Generation of a New Congenic Mouse Strain to Test the Relationships Among Serum Insulin-like Growth Factor I, Bone Mineral Density, and Skeletal Morphology In Vivo","volume":"17","author":"Bouxsein ML","unstructured":"Bouxsein, M.L., et al.: Generation of a New Congenic Mouse Strain to Test the Relationships Among Serum Insulin-like Growth Factor I, Bone Mineral Density, and Skeletal Morphology In Vivo. J. Bone Miner. Res. no. 17(4), 570\u2013579 (Apr. 2002). https:\/\/doi.org\/10.1359\/jbmr.2002.17.4.570","journal-title":"J. Bone Miner. Res."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402490101","author":"Cheng JB","year":"2004","unstructured":"Cheng, J.B., Levine, M.A., Bell, N.H., Mangelsdorf, D.J., Russell, D.W.: Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase, Proceedings of the National Academy of Sciences, vol. 101, no. 20, pp. 7711\u20137715, May (2004). 10.1073\/pnas.0402490101"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEP.2024.04.034","author":"Harrison SA","year":"2024","unstructured":"Harrison, S.A., Rolph, T., Knott, M., Dubourg, J.: FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond, J Hepatol, vol. 81, no. 3, pp. 562\u2013576, Sep. (2024). 10.1016\/J.JHEP.2024.04.034"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.1200797109","author":"Wei W","year":"2012","unstructured":"Wei, W., et al.: Feb., Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3, Proc Natl Acad Sci U S A, vol. 109, no. 8, pp. 3143\u20133148, (2012). 10.1073\/PNAS.1200797109"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.1200797109","author":"Wei W","year":"2012","unstructured":"Wei, W., et al.: Feb., Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3, Proc Natl Acad Sci U S A, vol. 109, no. 8, pp. 3143\u20133148, (2012). 10.1073\/PNAS.1200797109"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"115913","DOI":"10.1016\/J.BONE.2021.115913","article-title":"PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss","volume":"147","author":"Baroi S","unstructured":"Baroi, S., Czernik, P.J., Chougule, A., Griffin, P.R., Lecka-Czernik, B.: PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss. Bone. no. 147, 115913 (Jun. 2021). 10.1016\/J.BONE.2021.115913","journal-title":"Bone"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021119-034332","author":"Robling AG","year":"2020","unstructured":"Robling, A.G., Bonewald, L.F.: The Osteocyte: New Insights, Annu Rev Physiol, vol. 82, no. Volume 82, pp. 485\u2013506, 2020, (2020). https:\/\/doi.org\/10.1146\/annurev-physiol-021119-034332"},{"issue":"4","key":"ref28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1084\/JEM.186.4.489","article-title":"Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts","volume":"186","author":"Kameda T","unstructured":"Kameda, T., et al.: Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. no. 186(4), 489\u2013495 (Aug. 1997). 10.1084\/JEM.186.4.489","journal-title":"J. Exp. Med."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu094","author":"Schoenaker DAJM","year":"2014","unstructured":"Schoenaker, D.A.J.M., Jackson, C.A., Rowlands, J.V., Mishra, G.D.: Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents, Int J Epidemiol, vol. 43, no. 5, pp. 1542\u20131562, Oct. (2014). 10.1093\/ije\/dyu094"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7775325\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7775325\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:51:52Z","timestamp":1763992312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7775325\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":29,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7775325\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,11,24]]},"subtype":"preprint"}}